PlA1/A2 polymorphism of platelet glycoprotein IIIa and risk of acute coronary syndromes in heterozygous familial hypercholesterolemia

被引:10
|
作者
Cenarro, A [1 ]
Casao, E
Civeira, F
Jensen, HK
Faergeman, O
Pocoví, M
机构
[1] Univ Zaragoza, Dept Biochem & Mol & Cellular Biol, E-50009 Zaragoza, Spain
[2] Hosp Miguel Servet, Dept Internal Med, Zaragoza, Spain
[3] Aarhus Amtssygehus Univ Hosp, Dept Internal Med & Cardiol, Aarhus, Denmark
关键词
familial hypercholesterolemia; glycoprotein IIIa polymorphism; LDL receptor mutation; coronary heart disease;
D O I
10.1016/S0021-9150(98)00283-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Familial hypercholesterolemia (FH) is an autosomal inherited disorder caused by different mutations in the low density lipoprotein (LDL) receptor gene. It has been demonstrated that there is an increased risk of coronary heart disease (CHD) in heterozygous FH subjects, although this excess CHD is not only explained by the LDL-cholesterol concentration or the class of the LDL-receptor mutation. To investigate if a common polymorphism at the platelet glycoprotein (GP) IIIa gene locus could be related to CHD phenotypic variation in heterozygous FH, we have carried out a case-control study. We have studied 40 cases and 40 controls matched for age, sex and genetic defect in the LDL-receptor gene. Allele frequency of p1(A2) polymorphism for cases and controls was 20 and 22.5%, respectively, and the difference was not significant. In conclusion, our data do not support any association between the GP IIIa polymorphism and the increased prevalence of acute coronary syndromes in the heterozygous FH subjects. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 50 条
  • [41] Platelet glycoprotein receptor IIIa polymorphism PLa1a2 and vascular risk:: A meta-analysis
    Di Castelnuovo, A
    Donati, MB
    Iacoviello, L
    THROMBOSIS AND HAEMOSTASIS, 1999, : 386 - 386
  • [42] A meta-analysis of studies on the association of the platelet PlA polymorphism of glycoprotein IIIa and risk of coronary heart disease
    Burr, D
    Doss, H
    Cooke, GE
    Goldschmidt-Clermont, PJ
    STATISTICS IN MEDICINE, 2003, 22 (10) : 1741 - 1760
  • [43] THE PLA1/A2 POLYMORPHISM OF GLYCOPROTEIN IIA AS AN AGE-DEPENDENT RISK FACTOR FOR MYOCARDIAL INFARCTION: A META-ANALYSIS
    Floyd, Christopher Nicholas
    Mustafa, Agnesa
    Ferro, Albert
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A261 - A261
  • [44] Glycoprotein IIIa PIA1/A2 polymorphism is not a risk factor for coronary artery disease.
    Laule, M
    Stangl, K
    Cascorbi, I
    Stangl, V
    Felix, SB
    Baumann, G
    CIRCULATION, 1998, 98 (17) : 394 - 394
  • [45] The influence of the platelet PIA2 polymorphism on the response to a glycoprotein IIb/IIIa antagonist in patients with acute coronary syndromes.
    O'Connor, F
    Molloy, MA
    Shields, DC
    Fitzgerald, DJ
    BLOOD, 1999, 94 (10) : 244A - 244A
  • [46] P1a1/a2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty
    Mamotte, CDS
    van Bockxmeer, FM
    Taylor, RR
    AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (01): : 13 - 16
  • [47] Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
    Bhatt, DL
    Topol, EJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (12): : 1549 - 1558
  • [48] Emerging Treatment of Acute Coronary Syndromes with Platelet Glycoprotein IIB/IIIA Inhibitors
    Matthew T. Roe
    David J. Moliterno
    Journal of Thrombosis and Thrombolysis, 1999, 7 : 247 - 257
  • [49] Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
    Topol, E
    Califf, R
    Simoons, M
    Diaz, R
    Paolasso, E
    Klein, W
    Boland, J
    DeBacker, G
    Armstrong, P
    Corbalan, R
    Isaza, D
    Widimsky, P
    Urrutia, C
    Luomanmäki, K
    Vahanian, A
    Karsch, K
    Cokkinos, D
    Karatasakis, G
    Toutouzas, P
    Rodas, M
    Keltai, M
    Chierchia, S
    Silva, E
    Erikssen, J
    Ruzyllo, W
    Stepinska, J
    Ribeiro, VD
    Fernandez-Ortiz, A
    Macaya, C
    Goy, J
    Deckers, J
    Skene, A
    Wilcox, R
    Guerci, A
    Harrington, R
    Hochman, J
    Holmes, D
    Kleiman, N
    Kopecky, S
    Lee, K
    Lincoff, A
    Ohman, E
    Pepine, C
    Isea, J
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (07): : 436 - 443
  • [50] Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB IIIA inhibitors
    Roe, MT
    Moliterno, DJ
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 1999, 7 (03) : 247 - 257